Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study At enrollment, the treatment groups had no statistically significant differences in patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback